28th Aug 2026 10:13
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.
----------
Main Market small-cap winners
----------
McBride PLC, up 17% at 196.1p, hails earnings "accretive" deal win
Gem Diamonds Ltd, up 16% at 5.5p
Contango Holdings PLC, up 16% at 0.725p
Imaging Biometrics Ltd, up 14% at 0.8p, says US medical centre adopts brain tumour imaging software offering
Headlam Group PLC, up 6.8% at 9.955p, fell 11% on Thursday
----------
Main Market small-cap losers
----------
Bluebird Mining Ventures Ltd, down 13% at 0.0525p
Vox Valor Capital Ltd, down 8.9% at 0.175p
Macau Property Opportunities Fund Ltd, down 6.3% at 4.8p
Aminex PLC, down 6.3% at 1.5p
Kendrick Resources PLC, down 5.0% at 7.125p
----------
AIM winners
----------
Sunda Energy PLC, up 41% at 3.25p
GENinCode PLC, up 24% at 1.175p, hails "milestone" clinical results
Mothercare PLC, up 14% at 0.8p
Kooth PLC, up 10% at 179p
Shield Therapeutics PLC, up 8.2% at 5.95p
----------
AIM losers
----------
Forgent PLC, down 21% at 0.0075p, exercises Peak Hill option and announces fundraise
GenIP PLC, down 15% at 2.9p, half-year loss widens
Jarvis Securities PLC, down 13% at 7p, "unlikely" to realise any value from Jarvis Investment Management Ltd
Phoenix Copper Ltd, down 7.7% at 0.6p
FIH Group PLC, down 6.9% at 170p
----------
Small-cap and AIM movers in focus:
----------
GENinCode, up 24% at 1.175p, 12-month range 0.75p-5.50p. The predictive genetics company hails clinical results presented at the 2026 European Society of Cardiology annual congress. "The results showed a major advance in the prediction and potential prevention of coronary artery disease using the company's CARDIO inCode-Score Coronary Artery Disease Polygenic Risk Score test," it adds.
----------
McBride, up 17% at 196.1p, 12-month range 106.20p-199.07p. It lands a strategic partnership with EH Group BV, or Vestacy, which owns home care brands Air Wick, Calgon, Cillit Bang and Mortein. The supplier of private label products for household and professional cleaning expects the deal to be "materially earnings accretive". "At maturity, the new agreement, when combined with other contracts being signed in parallel, is expected to generate revenues annualising at GBP170 million during H2 FY28 from volumes at the two acquired sites and from volumes currently produced by a third-party supplier," it says. "Profit margins are expected to be in line with existing McBride levels, delivering EPS growth consistent with revenue growth."
----------
Imaging Biometrics, up 14% at 0.8p, 12-month range 0.40p-1.40p. The medical imaging technology company enters an annual subscription agreement with a "major academic medical centre" in the Midwest region of the US. It is for usage of IB Clinic, the firms automated brain tumour imaging software.
----------
Jarvis Securities, down 13% at 7p, 12-month range 6.50p-24.00p. The firm, which in May announced a process to explore the sale of its Jarvis Investment Management unit, says "no offers have emerged, and the sale process has now been terminated". "The wind down process of JIML will continue as previously announced, but the directors consider it is now unlikely that Jarvis will realise any further value from its investment in JIML. The directors are considering the future of the company, and in the absence of a suitable opportunity to create future shareholder value in the short term, they intend to make arrangements to return any remaining capital to shareholders later in the year," Jarvis says.
----------
Watkin Jones PLC, down 5.7% at 16.97p, 12-month range 16.80p-35.15p. The developer says a number of transactions it hoped to conclude before the end of its financial year are now likely to not be sealed in time. As a result, Watkin Jones expects adjusted operating profit for the year to September 30 to be "at a similar level" to what it achieved in the first half. Half-year adjusted operating profit amounted to GBP400,000. In July, it reported it was "actively engaged with investors on a small number of transactions which have the potential to conclude in the final quarter". The conclusion of these deals was needed in order for Watkin Jones "to deliver adjusted operating profit progression in the second half over the first half", it said at the time. The firm says on Friday: "Whilst investor engagement in each of these schemes remains active, the board has concluded that it is now unlikely that all of these transactions will be finalised by the year end. As a result, the group is expected to deliver adjusted operating profit for the full year at a similar level to H1."
----------
By Eric Cunha, Alliance News news editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Contango HdgImaging BioGem Diamonds DiMcbrideBluebird Mining VenturesVox Valor CapMacau PropertyAminexKendrick ResourcesSunda EnergyGenincodeMothercareKooth PlcShield TheraForgentGenip PlcJarvis SecuritiesPhoenix Copper LimitedFih GroupWatkin Jones